Edwards Lifesciences Corp.
- EW · NYSE
- Orthopedic, Prosthetic & Surgical Appliances & Supplies
- Irvine, CA
- 16,000 employees
- CIK 0001099800
Updated from SEC filings through
Top things to know
Executives
- Bernard Zovighian CEO of Edwards Lifesciences 8-K, 2026-11-04
- Bernard J. Zovighian CEO 4, 2026-07-27
- Theodora Mistras CVP, Chief Financial Officer 4, 2026-07-10
- Scott B. Ullem CVP, Chief Financial Officer 4, 2026-05-11
- Andrew M. Dahl SVP, Corporate Controller 4, 2026-09-14
- Wayne Markowitz CVP, JAPAC 4, 2026-09-14
What leadership is saying
“We delivered strong third-quarter growth of 11.2% which exceeded expectations, with broad-based performance across our businesses and regions, giving us the confidence to raise our full-year outlook”
Earnings press release (8-K Ex. 99.1), filed November 4, 2026
Edwards Lifesciences Corp is a U.S. public company in orthopedic, prosthetic & surgical appliances & supplies (SIC 3842), headquartered in Irvine, CA. It trades as EW on NYSE. Revenue was $6.1B in the fiscal year ending December 31, 2025, +11.5% from the year before. It reported about 16,000 employees. Bernard Zovighian is CEO of Edwards Lifesciences.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $6.1B 10-K, 2026-02-25 | $5.4B 10-K, 2026-02-25 | $5.0B 10-K, 2026-02-25 | $4.5B 10-K, 2025-02-28 | $5.2B 10-K, 2024-02-12 |
| Operating income | $1.3B 10-K, 2026-02-25 | $1.4B 10-K, 2026-02-25 | $1.3B 10-K, 2026-02-25 | $1.5B 10-K, 2025-02-28 | $1.7B 10-K, 2024-02-12 |
| SG&A | $2.1B 10-K, 2026-02-25 | $1.8B 10-K, 2026-02-25 | $1.6B 10-K, 2026-02-25 | $1.4B 10-K, 2025-02-28 | $1.5B 10-K, 2024-02-12 |
| Net income | $1.1B 10-K, 2026-02-25 | $4.2B 10-K, 2026-02-25 | $1.4B 10-K, 2026-02-25 | $1.5B 10-K, 2025-02-28 | $1.5B 10-K, 2024-02-12 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Bernard Zovighian Chief Executive Officer at Edwards Lifesciences | CEO of Edwards Lifesciences | 8-K, 2026-11-04 |
| Bernard J. Zovighian | CEO | 4, 2026-07-27 |
| Kieran T. Gallahue | Named in proxy bio: Former Chairman and CEO, CareFusion Corporation | DEF 14A, 2026-03-26 |
| Leslie C. Davis | Named in proxy bio: CEO and President, University of Pittsburgh Medical Center | DEF 14A, 2026-03-26 |
| Nicholas J. Valeriani | Named in proxy bio: Former CEO, Gary and Mary West Health Institute | DEF 14A, 2026-03-26 |
| Paul A. LaViolette | Named in proxy bio: CEO, Pulse Biosciences, Inc., Managing Partner and COO, SV Health Investors LLC | DEF 14A, 2026-03-26 |
| Steven R. Loranger | Named in proxy bio: Former Chairman, President and CEO , ITT Corporation | DEF 14A, 2026-03-26 |
| Theodora Mistras | CVP, Chief Financial Officer | 4, 2026-07-10 |
| Scott B. Ullem | CVP, Chief Financial Officer | 4, 2026-05-11 |
| Annette M. Brüls | Named in proxy bio: Corporate Vice President, Europe, Middle East, Africa, Canada and Latin America (EMEACLA) | DEF 14A, 2026-03-26 |
| Daniel Lippis | Named in proxy bio: Corporate Vice President, Transcatheter Aortic Valve Replacement (TAVR) | DEF 14A, 2026-03-26 |
| Ramona Sequeira | Named in proxy bio: Former President, Global Portfolio Division, Takeda Pharmaceutical Company | DEF 14A, 2026-03-26 |
| Wayne T. Markowitz | Named in proxy bio: Corporate Vice President, Japan, Greater China, and Asia Pacific (JAPAC) | DEF 14A, 2026-03-26 |
| Andrew M. Dahl | SVP, Corporate Controller | 4, 2026-09-14 |
| Wayne Markowitz | CVP, JAPAC | 4, 2026-09-14 |
| Daniel J. Lippis | CVP, TAVR | 4, 2026-09-11 |
What Edwards Lifesciences Corp does
Edwards Lifesciences Corporation is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence, and meaningful partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most. Edwards Lifesciences has been a leader in our field for over six decades.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 575.0 million (as of October 31, 2026) | 10-Q, November 4, 2026 |
|---|---|---|
| Public float | $45.9B (as of June 30, 2025) | 10-K, February 25, 2026 |
| Reportable segments | 4 (period ending September 30, 2026) | 10-Q, November 4, 2026 |
| Latest proxy statement | Meeting May 7, 2026 (filed March 26, 2026) | DEF 14A, March 26, 2026 |
| Auditor | PricewaterhouseCoopers LLP (Irvine, California) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| November 9, 2026 | Bernard J. Zovighian CEO | Sale | 23,100 | $2.4M | Form 4, November 9, 2026 |
| November 9, 2026 | Donald E. Bobo Jr CVP,Strategy/Corp Development | Sale | 48,900 | $5.0M | Form 4, November 9, 2026 |
| October 8, 2026 | Daniel J. Lippis CVP, TAVR | Sale | 619 | $53K | Form 4, October 8, 2026 |
| September 11, 2026 | Daniel J. Lippis CVP, TAVR | Sale | 619 | $54K | Form 4, September 11, 2026 |
| August 31, 2026 | Andrew M. Dahl SVP, Corporate Controller | Sale | 544 | $50K | Form 4, August 31, 2026 |
| August 28, 2026 | Annette Bruls CVP, EMEACLA | Sale | 2,644 | $238K | Form 4, August 28, 2026 |
| August 26, 2026 | Daveen Chopra CVP, TMTT, Surgical & IHFM | Sale | 31,800 | $2.9M | Form 4, August 26, 2026 |
| August 26, 2026 | Wayne Markowitz CVP, JAPAC | Sale | 1,240 | $113K | Form 4, August 26, 2026 |
Recent 8-K events
- 8-K filed 2026-11-04
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-08-28
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-07-23
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-05-08
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-05-04
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-04-23
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-02-10
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-01-12
- Item 7.01 Regulation FD disclosure
- 8-K filed 2025-10-30
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 7.01 Regulation FD disclosure
- 8-K filed 2025-10-30
- Item 2.02 Results of operations and financial condition (earnings release)
Frequently asked questions about Edwards Lifesciences Corp
- What does Edwards Lifesciences Corp do?
- In its own words, from Item 1 of its 10-K: "Edwards Lifesciences Corporation is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence, and meaningful partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most. Edwards Lifesciences has been a leader in our field for over six decades."
- What is Edwards Lifesciences Corp's revenue?
- $6.1B for the fiscal year ending December 31, 2025, from its 10-K filed February 25, 2026.
- Is Edwards Lifesciences Corp profitable?
- Edwards Lifesciences Corp reported net income of $1.1B for the fiscal year ending December 31, 2025.
- How many employees does Edwards Lifesciences Corp have?
- About 16,000 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of Edwards Lifesciences Corp?
- Bernard Zovighian, CEO of Edwards Lifesciences, as named in a 8-K filed November 4, 2026.
- Who is the CFO of Edwards Lifesciences Corp?
- Theodora Mistras, CVP, Chief Financial Officer, as named in a 4 filed July 10, 2026.
- Where is Edwards Lifesciences Corp headquartered?
- Irvine, CA.
- What is Edwards Lifesciences Corp's stock ticker?
- EW on NYSE.
- What industry is Edwards Lifesciences Corp in?
- Orthopedic, Prosthetic & Surgical Appliances & Supplies, SIC code 3842.
- What is Edwards Lifesciences Corp's website?
- edwards.com.
- When does Edwards Lifesciences Corp report earnings next?
- February 15, 2027. Source: estimate_8k_pattern.
- Is Edwards Lifesciences Corp a public company?
- Yes. Edwards Lifesciences Corp files with the SEC under CIK 0001099800 and trades as EW.
- Who audits Edwards Lifesciences Corp?
- PricewaterhouseCoopers LLP, Irvine, California, as named in its latest annual report (10-K).
- How many shares of Edwards Lifesciences Corp are outstanding?
- 575.0 million shares as of October 31, 2026, from its 10-Q filed November 4, 2026.
- What is Edwards Lifesciences Corp's public float?
- $45.9B as of June 30, 2025, as reported on the cover of its 10-K filed February 25, 2026.
- How many business segments does Edwards Lifesciences Corp report?
- 4 reportable segments for the period ending September 30, 2026, from its 10-Q filed November 4, 2026.
- When is Edwards Lifesciences Corp's annual shareholder meeting?
- May 7, 2026, per its proxy statement (DEF 14A) filed March 26, 2026.
- Have Edwards Lifesciences Corp insiders traded stock recently?
- Since July 28, 2025, officers and directors reported 46 open-market sales worth about $36.4M and 0 purchases on Forms 4 and 5. The most recent: Bernard J. Zovighian (CEO) sold 23,100 shares on November 9, 2026.